INTRODUCTION
Severe neonatal pulmonary hypertension affects approximately 1 in 1000 term neonates. 1 Newborn infants with persistent pulmonary hypertension of the newborn (PPHN) often have hypoxemia despite adequate respiratory drive, due to right-to-left shunting or ventilation-perfusion mismatch. If oxygenation is inadequate despite a high concentration of inspired oxygen (FiO 2 ) or if respiratory acidosis or apnea occurs, the infant is intubated and mechanically ventilated. If oxygenation is inadequate despite increasing ventilator settings, rescue therapies such as inhaled nitric oxide (NO) or high-frequency ventilation are often attempted before extracorporeal membrane oxygenation (ECMO). Despite current therapies including high-frequency ventilation, inhaled NO, and ECMO, mortality is high at 10% to 20%. 1 -3 Morbidity occurs in 10% to 20% of severely affected neonates. 2 -4 NO inhalation has undergone several large multicenter clinical trials in neonates with encouraging results. 2,5 -7 The use of NO inhalation has been shown to decrease ECMO use, without prolongation of mechanical ventilation or hospital stay. 8 These studies have evaluated NO administration to neonates already on mechanical ventilation.
One of the problems with this approach to management is that mechanical ventilation by itself may lead to or potentiate lung injury and predispose to chronic lung disease. 9, 10 The high mean airway pressures that are often used increase pulmonary vascular resistance, decreasing pulmonary blood flow and cardiac output. It is possible that administration of inhaled NO to neonates with abnormal gas exchange earlier, rather than later as a rescue therapy, might accelerate the transition of the circulation from fetal to neonatal physiology and improve oxygenation. This may in turn decrease the need for mechanical ventilation and its associated morbidity.
This study was designed to confirm the hypotheses that NO administration by oxygen hood in a neonatal porcine model of pulmonary hypertension induced either by hypoxia or by infusion of group B streptococci (GBS) would demonstrate hemodynamic efficacy and feasibility.
METHODS
The animal research protocol was approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.
Preparation of the Chronically Instrumented Animal Model
Piglets (3 to 4 weeks of age; 4 to 8 kg weight) were used for this study. A left thoracotomy was performed on anesthesized piglets and the pericardium opened. An ultrasonic flow transducer (Transonic Systems, Ithaca, NY) was affixed around the main
OBJECTIVE:
To test the hemodynamic efficacy and feasibility of nitric oxide ( NO ) administration by oxygen hood in neonatal pulmonary hypertension.
STUDY DESIGN:
A double -hood apparatus was used in which a combination of NO, O 2 , and N 2 was introduced into the inner hood and suctioned from the outer hood. Chronically instrumented non -intubated piglets were exposed to 10% O 2 ( hypoxia; n = 8 ) or group B streptococci infusion ( GBS; n = 5 ) to produce pulmonary hypertension and were then exposed to 20 ppm NO.
RESULTS:
NO decreased ( > 50% ) pulmonary artery pressure and vascular resistance in both hypoxia -and GBS -induced pulmonary hypertension, with minimal effects on systemic arterial pressure and cardiac output. NO administration could be performed without detectable environmental leakage.
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pulmonary artery, and catheters inserted into the main pulmonary artery and left atrium. The ductus arteriosus was fibrosed by this age in all piglets. Aortic and inferior vena cava catheters were placed through the left femoral artery and vein, respectively, through a left groin incision. All catheters and the flow transducer cable were tunneled to a left flank incision and stored in a pouch secured to the skin. The chest and groin incisions were then closed. After completion of surgery, animals were allowed to recover for 3 to 4 days with appropriate postoperative care and analgesia. Catheters were flushed daily with normal saline containing 10 U/ml heparin, and 5 mg/kg gentamicin and 50 mg/kg ampicillin were administered daily for infection prophylaxis. Experiments were performed on sedated non-intubated piglets after 3 to 4 days of recovery from surgery. Piglets were sedated with diazepam 1 to 2 mg/kg and pentobarbital 5 to 15 mg/kg, and subsequently received smaller doses every 30 to 60 minutes if excessive movement was observed. Sedation at these doses had minimal effect on systemic or pulmonary hemodynamics. The flow transducer was attached to a T101 Ultrasonic Blood Flowmeter (Transonic Systems) and all catheters were connected to precalibrated pressure transducers (Spectramed P23XL, Oxnard, CA). Systemic (SAP), pulmonary artery (PAP), left atrial (LAP), and central venous pressures (CVP), as well as mean pulmonary artery flow (QPA), were continuously monitored using physiologic recorders (Gould-Brush 2400S, Oxnard, CA).
The Double-Hood NO Delivery System We developed a ''double-hood'' device for the administration of inhaled NO (Figure 1 ). The O 2 /N 2 /NO blend was administered to the inner hood and suctioned from the outer hood (and inner hood via NO/NO 2 sensor). The inner hood was made of Plexiglas (10 in. diameter; Olympic oxyhood; Olympic Medical, Seattle, WA) and the outer hood was made of plastic sheeting (12Â12Â10 in.; NOVA tenthouse oxygen tent; Nova Health Systems, Utica, NY). O 2 (1 to 2 l/min) and N 2 (8 to 9 l/min), adjustable by flowmeter from 0 to 15 l/min, were delivered from individual cylinders and were blended with a NO/N 2 gas mixture (800 ppm NO and balance N 2 ; Ohmeda PPD, Liberty Corner, NJ) to yield a constant total flow of 10 l/min into the inner hood, which the animal breathed. A suction apparatus was attached to the outer hood that suctioned (scavenged) the gases from the outer hood at approximately 4 to 5 l/min. The NO/NO 2 sensor (range 0.05 to 99.9 ppm; SensorNOx; Sensormedics BV, 3720 AG Bilthoven, the Netherlands) in the inner hood also suctioned approximately 4 l/min. Both suction systems were attached to a vented connector attached to the wall suction that entrained room air and was regulated to a negative pressure of À9 to À10 cm H 2 O. The NO/NO 2 sensor and an O 2 analyzer continuously monitored NO, NO 2 , and O 2 concentrations in the inner hood. NO, NO 2 , and O 2 concentrations were monitored periodically between the inner and outer hoods, on the outer surface of the outer hood, and 30 cm from the front of the hood (in room air). The O 2 concentration in the inner hood could be adjusted with this apparatus from 0% to 96% (with simultaneous delivery of 20 ppm NO) or 98% to 99% (with no NO delivery) by adjusting the proportion of oxygen and nitrogen in the inflow gas while monitoring the oxygen concentration in the inner hood using the oxygen analyzer. The CO 2 concentration in the inner hood was below detectable limits ( <0.25%) at a gas flow of 10 l/min (to the inner hood) with scavenging from the outer hood.
The advantage of the double-hood model with a scavenging system, as compared to a single hood with no scavenging system, was that there was more stability of gas concentrations in the inner hood and less leakage of NO/NO 2 into the immediate external environment. The outer hood was not tightly sealed, as that side of the outer hood was plastic sheeting draped over the neck. These hoods permit easy access to the infant and some entrainment is considered acceptable. As the inflow is more than the outflow (suction), the net flow of gas is out of the hood rather than inwards. The outer hood is not a perfect seal to outside air but created a ''buffer zone'' where most of the air between the hoods was from the inflow gas and the rest was entrained room air.
Hypoxia-Induced Pulmonary Hypertension
The O 2 concentration was adjusted to 21% in the inner hood (O 2 at 2 l/min combined with nitrogen at 8 l/min) and baseline recordings obtained. Hypoxic conditions were then created in the inner hood by decreasing O 2 to 10%. After 5 to 10 minutes of recording, once a plateau of pulmonary arterial pressure was attained, 20 ppm NO was introduced into the inner hood during continuing hypoxia. NO was administered for 5 minutes, discontinued for 10 minutes, and then reintroduced for 10 minutes. After the final 10 minutes of hypoxic exposure with NO, the O 2 concentration was increased to 21% and the NO was discontinued. Eight piglets were used for this experiment, with one continuous Figure 1 . Double -hood apparatus used for the delivery of NO. Blended nitrogen /oxygen at 9 to 10 l /min was mixed with NO and delivered to the inner hood. The NO /NO 2 analyzer suctioned 4 l /min from the inner hood and the scavenging system suctioned 4 to 5 l /min from the outer hood.
tracing obtained from each animal. Arterial blood gases were obtained at baseline, and 5 minutes after each intervention (hypoxia, NO administration, return to baseline) was initiated.
To evaluate if hemodynamic responses were dependent on the dose of NO in this model, four piglets were exposed to hypoxia, and then administered 3 ppm NO for 10 minutes followed by 20 ppm NO for 10 minutes. Hypoxia and NO were then discontinued. NO concentrations of less than 3 ppm were not tested as they could not be accurately delivered due to the extremely low flow.
GBS-Induced Pulmonary Hypertension
GBS Type Ib Strain 501, originally isolated from the cerebrospinal fluid of an infant with late-onset sepsis and meningitis, was grown to late logarithmic phase in a chemically defined medium for 4 to 5 hours. 11 The cultures were heat killed at 808C for 30 minutes, washed twice in phosphate-buffered saline (PBS), and resuspended in PBS at an optical density equivalent to 1Â10 9 colony-forming units (cfu) /ml.
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Five piglets were used for this experiment. After baseline recording for 5 minutes and ensuring stability of the recordings, the GBS preparation was infused at 2 ml/kg per hour for 10 minutes. After 5 to 10 minutes, once a plateau in pulmonary arterial pressure was attained, 20 ppm NO was administered for 5 minutes. NO was then discontinued and recordings continued for 10 minutes, until a new plateau in pulmonary arterial pressure was obtained.
Arterial blood gases were obtained at baseline, and 5 minutes after each intervention (GBS infusion, NO administration, return to baseline) was initiated.
Measurements and Analysis
Five animals were required in each model in order to detect a 40% change in the continuous variables (PAP, SAP, or QPA) at 80% power, with a p value of <0.05. Eight animals were used for each model to allow for experimental losses or technical problems in measurement.
All monitored hemodynamic variables were read from the strip charts (as electronic means from phasic tracings) just before experimental conditions were changed. Cardiac index (CI) was calculated as pulmonary artery flow/body weight. Systemic (SVRI) and pulmonary vascular resistance indices (PVRI) were calculated as (SAPÀCVP) /CI and (PAPÀLAP) /CI, respectively.
One-way repeated measures analysis of variance (RM ANOVA), followed by Tukey's multiple comparison test, was used for statistical analysis. All data are expressed as mean±SEM. A p value <0.05 was considered statistically significant.
RESULTS

Effect of NO on Hypoxic Pulmonary Hypertension
Hypoxia increased PAP above baseline (from 14±2 to 37±2 mm Hg; p<0.05) (Figure 2) . Inhaled NO at 20 ppm reduced PAP almost to baseline (18±2 mm Hg; p<0.05 vs hypoxia). NO discontinuation elevated PAP (30±2 mm Hg) again, although not to its initial peak (p<0.05 vs initial peak). Reinstitution of NO decreased PAP to baseline (14±1 mm Hg). The subsequent return to normoxia (without NO) did not significantly change PAP (12±2 mm Hg; p=NS versus baseline and hypoxia+NO). The cardiac index was 10% to 20% higher during the hypoxic exposure (p<0.05), and was not significantly affected by NO administration. SAP was stable throughout the experiment (p>0.05). The marked decreases with NO in PAP were paralleled by equivalent decreases in the PVRI, whereas SVRI changed <10% from baseline.
At baseline, arterial blood gases (n=4) were pH 7.45±0.02/pO 2 90±5 Torr/pCO 2 39±1 Torr/HCO 3 28±1 mEq/SaO 2 97±0.5%. Hypoxia led to lower pO 2 and tachypnea, with resulting mild respiratory alkalosis (pH 7.52±0.03/pO 2 24±1 Torr/pCO 2 30±1 Torr/HCO 3 25±2 mEq/SaO 2 51±5%). Hypoxia combined with NO administration did not significantly change blood gases (pH 7.48±0.01/pO 2 25±2 Torr/pCO 2 27±1 Torr/HCO 3 22±3 mEq/ SaO 2 53±4). On return to room air, blood gases were similar to baseline (pH 7.41±0.01/pO 2 72±3 Torr/pCO 2 36±2 Torr/HCO 3 224±3 mEq/SaO 2 94±2).
NO at 3 ppm decreased hypoxia-induced pulmonary hypertension from 34±7 to 19±5 mm Hg (p<0.05). An increase in NO from 3 to 20 ppm did not decrease PAP appreciably (from 19±5 to 16±3 mm Hg; p=0.86).
Effect of NO on GBS-Induced Pulmonary Hypertension
GBS infusion elevated PAP (16±2 to 34±4 mm Hg; p<0.05) (Figure 3 ). NO inhalation decreased PAP to baseline (17±2 mm Hg; p<0.05 vs GBS without NO). Discontinuation of NO elevated PAP again to its previous peak (35±2 mm Hg; p<0.05 vs GBS with NO).
Associated with the increase of PAP with GBS, there was a small increase in SAP (84±5 to 93±4 mm Hg; p<0.05), which decreased with NO (85±6 mm Hg; p<0.05 vs without NO) and increased with NO withdrawal (91±5 mm Hg). However, no significant differences were noted in the cardiac index or SVRI (p>0.05 by RM ANOVA). The PVRI, which increased to 240% of baseline with the GBS infusion (p<0.05 vs baseline), decreased almost to baseline with NO (110% of baseline, p=NS versus baseline) and returned to 250% of baseline on discontinuation of NO (p<0.05 vs baseline).
At baseline, arterial blood gases (n=3) were pH 7.46±0.02/pO 2 84±1 Torr/pCO 2 38±2 Torr/HCO 3 27±0.5 mEq/SaO 2 97±0.5%. GBS infusion (pH 7.48±0.02/pO 2 70±8 Torr/pCO 2 45±3 Torr/ HCO 3 33±3 mEq/SaO 2 94±2%) and GBS combined with NO administration did not significantly change blood gases (pH 7.51±0.02/pO 2 62±9 Torr/pCO 2 41±2 Torr/HCO 3 33±3 mEq/ SaO 2 92±3).
NO Delivery and Leakage
Accurate delivery of NO was feasible using the double-hood apparatus. NO concentrations in the presence of a relatively Ambalavanan et al.
Feasibility of Nitric Oxide Administration by Oxygen Hood in Neonatal Pulmonary Hypertension constant inflow (10 l/min) and outflow (scavenging) peaked within 1 minute, attained a stable plateau, and had a relatively slow wash-out (2 to 3 minutes to diminish to <1 ppm concentrations in the hood). Leakage of NO and NO 2 was negligible. When the inflow gas to the inner hood had a NO concentration of 25 ppm, the NO concentration in the inner hood was 20 ppm, with an associated NO 2 level of <1 ppm. The NO/NO 2 levels in the space between the hoods were 6.3±2/ An increase in the scavenging flow, in an attempt to eliminate all leakages of NO, was counterproductive as this led to an entrainment of room air into the hood, altering the oxygen concentrations.
Minor manipulations of the outer hood, as would occur with 
DISCUSSION
This study demonstrates that NO administration by the double-hood apparatus shows feasibility and hemodynamic efficacy in a neonatal animal model of pulmonary hypertension. NO selectively decreased pulmonary arterial pressures and resistance with minimal effects on systemic arterial pressures or resistance in spontaneously breathing, non-intubated neonatal piglets with either hypoxic-or GBSinduced pulmonary hypertension. Also, minimal leakage to the surrounding environment was noted, indicating that the doublehood technique is safe to persons in the vicinity. The concentrations of NO and NO 2 in the vicinity were well below the permissible exposure limits set by the Occupational Safety and Health Administration (OSHA) (NO: 25 ppm averaged over an 8-hour shift; NO 2 : maximum of 5 ppm) 12 and by the National Institute of Occupational Safety and Health (average NO 2 exposure over any 15-minute period not to exceed 1 ppm). 13, 14 There are some limitations to our study. First, the piglets in our study did not have intrinsic lung disease. The elevation in pulmonary pressures was due to either hypoxia or infusion of GBS antigens. Therefore, effects of any co-existing pulmonary pathology (such as GBS pneumonia or meconium aspiration) that may lead to ventilation-perfusion mismatching were not evaluated, although this would be of clinical relevance. However, as NO was markedly effective in both hypoxia-and GBS-induced pulmonary hypertension, which act through different mechanisms (hypoxia-induced via decreased NO and increased endothelin production, 15 and GBSinduced via increased thromboxane synthesis 16 ), it is likely that this technique would retain some efficacy even in the presence of ventilation-perfusion mismatch. It is possible that the delivery of NO by oxygen hood might be more suitable for neonates with idiopathic PPHN with clear lungs, rather than neonates with severe lung disease who may require ''lung recruitment'' for optimal effects of NO. Second, this study was intended only to evaluate feasibility, safety, and selected hemodynamic variables. We did not set out to evaluate the presence or the degree of right-to-left shunting, the need for mechanical ventilation, survival, or other outcomes of clinical importance. A third limitation (not of our study design, but of the technique) is that this technique would not be applicable to neonates with inadequate respiratory effort, hypercarbia, and respiratory acidosis. These neonates are likely to require mechanical ventilation from the onset. Another limitation is that these piglets at 3 to 4 weeks of age are more mature than human neonates at comparable age, and do not have the transitional circulation seen immediately after birth. However, we have noted from prior experiments that the pattern of physiologic responses to hypoxia and GBS is very similar from birth through 6 weeks of age in piglets. We are currently performing a masked randomized controlled trial in our neonatal intensive care unit evaluating this technique in hypoxemic neonates who have not yet required intubation. A valid assessment of efficacy of this technique in our human study will require a sample size of at least 40 to show an improvement in p a O 2 of at least 25% with 80% power, 0.05, assuming the standard deviation for p a O 2 is around 25% of the mean.
As we anticipated, when flow rates of 8 to 10 l/min were used in this double-hood model with scavenging, no accumulation of NO 2 was noted within the inner hood by continuous monitoring, and blood gas analyses revealed no hypercapnia due to rebreathing of CO 2 . It is possible that use of lower flow rates without scavenging might result in NO 2 accumulation. In the animal model, arterial blood gas analysis could not be used to evaluate the benefit of NO in this hypoxia model (because inspired O 2 was decreased, and no benefit of decreased PAP can be observed when alveolar pO 2 is low) or in the GBS model (because pulmonary pressures were subsystemic although elevated, with no right-to-left shunting). Therefore, these models mainly evaluated hemodynamic effects. Methemoglobinemia was not evaluated as it is not generally a clinical problem with inhalation of 20 ppm NO or less. 5, 7 The majority of the available literature on NO administration to neonates deal with mechanically ventilated infants, because NO has been used so far as a ''rescue'' therapy for infants not responding to conventional, and in some cases, high-frequency ventilation. Kakuya et al. 17 reported on the use of inhaled NO via a nasopharyngeal tube in an infant with a severely hypoplastic lung and end-stage pulmonary hypertension, in whom clinical improvement was maintained for 7 days with 18 to 22 ppm NO inhalation. Environmental NO levels were less than 0.06 ppm and NO 2 <0.3 ppm throughout the treatment, well within safety margins. However, due to entrainment of room air with varying patterns of respiration and varying contributions from mouth breathing, the actual delivered NO level by this method could not be ascertained with accuracy. An additional problem with this method is that the presence of a nasal catheter will partially or even completely occlude one nostril and increase airway resistance significantly (possibly by up to 50%), 18, 19 further compromising respiratory effort and oxygenation in a neonate with abnormal gas exchange. NO has also been delivered by a pulsed nasal cannula or face mask in older infants and children and shown to decrease pulmonary arterial pressures and resistance. 20 However, this method has the same flaws as delivery with a nasopharyngeal cannula. 17 The possible advantages of a double-hood technique are that the concentration of NO delivered is more accurate and easily controlled, especially during the weaning process, when it may be necessary to decrease NO concentrations in steps of 5 ppm or less. 21, 22 Also, concomitant administration of high concentrations of oxygen and its subsequent weaning are easier with an oxygen hood rather than with a cannula or face mask. Commercial devices, such as the INOvent (Ohmeda, Madison, WI), can be easily modified to deliver and servo-control NO and O 2 in a double-hood system.
The NO dose of 3 ppm produced hemodynamic effects comparable to those of 20 ppm, and it is possible that even lower doses may produce hemodynamic effects in this model, associated with even smaller NO and NO 2 leakage into the surrounding environment. This result is analogous to that reported by Finer et al., 23 who did not notice a difference in oxygenation in response to NO doses from 5 to 80 ppm. However, a detailed evaluation of dose-response in association with varying lung pathophysiology is necessary.
In summary, NO administration to neonates during mechanical ventilation has been shown to be effective 2,5 -8 and preliminary data on alternative methods of administration such as by nasal 20 or nasopharyngeal cannulae 17 and face masks 20 have been shown to be feasible. We have shown that NO administration using a doublehood model is simple and effective in a spontaneously breathing neonatal animal model. Clinical trials are in progress to investigate if this simple and non-invasive technique of NO administration is effective in human neonates with pulmonary hypertension.
